Thema: US29089Q1058
EBS, US29089Q1058
stock-5051155_1920.jpg - Foto: THN
Emergent BioSolutions stock faces lower 2026 revenue outlook
Emergent BioSolutions stock follows a third-quarter revenue drop and a lower full-year outlook. Cash flow and margin guidance offer counterpoints.
ad-hoc-news.de, vor 50 Minuten
EBS, US29089Q1058
HC Wainwright targets Emergent BioSolutions stock at USD ...
Results are due November 2, 2026. Emergent BioSolutions stock costs EUR 5.54 on October 20, 2026 at 7:31 p.m. CEST.
ad-hoc-news.de, 20.10.26 19:37 Uhr
EBS, US29089Q1058
Emergent BioSolutions stock falls 11.14 percent on October ...
H.C. Wainwright set USD 10.00 on September 9, 2026. Emergent BioSolutions stock stood at USD 6.38 on October 16, 2026, down 11.14 percent on NYSE.
ad-hoc-news.de, 17.10.26 19:23 Uhr
EBS, US29089Q1058
Emergent BioSolutions stock rises 3.91 percent with USD ...
Results are set for November 2, 2026. Emergent BioSolutions stock costs EUR 6.43 on October 15, 2026, up 3.91 percent on the NYSE.
ad-hoc-news.de, 15.10.26 22:18 Uhr
EBS, US29089Q1058
Pneumonic plague fears lift Emergent BioSolutions stock
Q2 revenue reached USD 234.30 million. Emergent BioSolutions stock was EUR 6.33 on October 7, 2026 versus EUR 6.17, plus 2.59 percent.
ad-hoc-news.de, 07.10.26 08:31 Uhr
EBS, US29089Q1058
Emergent BioSolutions stock gains 14.38 percent on outbreak ...
Emergent BioSolutions stock posted Q2 revenue of USD 234.3 million versus USD 177.5 million expected. Six analysts hold a USD 10.00 average target.
ad-hoc-news.de, 06.10.26 12:57 Uhr
EBS, US29089Q1058
Emergent repurchases debt. Emergent BioSolutions stock sits ...
Emergent repurchased USD 75 million of notes on September 3, 2026. Emergent BioSolutions stock sits 54.69 percent below its USD 14.06 high.
ad-hoc-news.de, 02.10.26 04:04 Uhr
